share_log

BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $24.67

BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $24.67

生物生命解決方案公司(納斯達克：BLFS)股價下跌至24.67美元
Financial News Live ·  2022/09/21 12:21

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $24.67, but opened at $24.12. BioLife Solutions shares last traded at $23.98, with a volume of 128 shares traded.

週三開盤前，生物生命解決方案公司(納斯達克代碼：BLFS-GET Rating)的股價大幅下挫。該股此前收盤報24.67美元，開盤報24.12美元。BioLife Solutions的股票尾盤報23.98美元，總成交量為128股。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

Separately, Cowen reduced their price objective on BioLife Solutions to $29.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $31.25.

另外，考恩在8月15日星期一的一份研究報告中將他們對BioLife Solutions的目標價格下調至29.00美元。一名投資分析師對該股的評級為賣出，三名分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，該公司目前的平均評級為“中等買入”，平均目標價為31.25美元。

Get
到達
BioLife Solutions
生物生命解決方案
alerts:
警報：

BioLife Solutions Stock Performance

BioLife解決方案股票表現

The company has a fifty day simple moving average of $21.91 and a 200 day simple moving average of $18.43. The company has a current ratio of 3.55, a quick ratio of 2.54 and a debt-to-equity ratio of 0.02.

該公司的50日簡單移動均線切入位為21.91美元，200日簡單移動均線切入位為18.43美元。該公司的流動比率為3.55，速動比率為2.54，債務權益比率為0.02。

Insiders Place Their Bets

內部人士下注

In other BioLife Solutions news, COO Greef Roderick De sold 9,158 shares of BioLife Solutions stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total transaction of $144,604.82. Following the transaction, the chief operating officer now directly owns 124,458 shares of the company's stock, valued at approximately $1,965,191.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
在BioLife Solutions的其他新聞中，首席運營官Greef Roderick de在一筆日期為7月12日(星期二)的交易中出售了BioLife Solutions的9,158股票。該股以15.79美元的平均價格出售，總成交金額為144,604.82美元。交易完成後，首席運營官現在直接持有該公司124,458股股票，價值約1,965,191.82美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過
this link
這個環節
. In other news, CRO Marcus Schulz sold 4,600 shares of the business's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.03, for a total value of $92,138.00. Following the transaction, the executive now directly owns 36,218 shares of the company's stock, valued at approximately $725,446.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
。在其他新聞方面，CRO馬庫斯·舒爾茨在8月3日星期三的交易中出售了4600股該公司的股票。股票以20.03美元的平均價格出售，總價值為92,138.00美元。交易完成後，這位高管現在直接持有該公司36,218股股票，價值約725,446.54美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過
the SEC website
美國證券交易委員會網站
. Also, COO Greef Roderick De sold 9,158 shares of the business's stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total value of $144,604.82. Following the completion of the transaction, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The disclosure for this sale can be found
。此外，首席運營官格里夫·羅德里克·德在日期為7月12日(星期二)的交易中出售了9,158股該公司股票。這些股票的平均價格為15.79美元，總價值為144,604.82美元。交易完成後，首席運營官現在直接擁有該公司124,458股，價值1,965,191.82美元。關於這次銷售的披露可以找到
here
這裏
. In the last three months, insiders have sold 18,401 shares of company stock valued at $313,764. 3.30% of the stock is currently owned by company insiders.
。在過去的三個月裏，內部人士已經出售了18,401股公司股票，價值313,764美元。3.30%的股份目前由公司內部人士持有。

Institutional Inflows and Outflows

機構資金流入和流出

A number of hedge funds and other institutional investors have recently made changes to their positions in BLFS. BlackRock Inc. raised its stake in BioLife Solutions by 1.6% during the 1st quarter. BlackRock Inc. now owns 3,712,680 shares of the medical equipment provider's stock worth $84,390,000 after buying an additional 57,623 shares during the period. Vanguard Group Inc. increased its holdings in BioLife Solutions by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 2,201,602 shares of the medical equipment provider's stock worth $50,043,000 after purchasing an additional 54,344 shares in the last quarter. Millennium Management LLC increased its holdings in BioLife Solutions by 45.3% during the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock worth $21,545,000 after purchasing an additional 486,631 shares in the last quarter. Marshall Wace LLP increased its holdings in BioLife Solutions by 4.2% during the 4th quarter. Marshall Wace LLP now owns 1,346,746 shares of the medical equipment provider's stock worth $50,193,000 after purchasing an additional 54,502 shares in the last quarter. Finally, State Street Corp increased its holdings in BioLife Solutions by 26.1% during the 2nd quarter. State Street Corp now owns 1,270,364 shares of the medical equipment provider's stock worth $17,544,000 after purchasing an additional 263,021 shares in the last quarter. 86.69% of the stock is owned by institutional investors and hedge funds.

一些對衝基金和其他機構投資者最近改變了他們在BLFS的頭寸。今年第一季度，貝萊德股份有限公司將其在BioLife Solutions的持股比例提高了1.6%。貝萊德股份有限公司目前持有這家醫療設備供應商3,712,680股股票，價值84,390,000美元，在此期間又購買了57,623股。先鋒集團在第一季度增持了2.5%的BioLife Solutions股份。先鋒集團(Vanguard Group Inc.)在上個季度增持了54,344股後，現在持有這家醫療設備供應商價值50,043,000美元的股票2,201,602股。千禧管理公司在第二季度增持了生物生命解決方案公司45.3%的股份。Millennium Management LLC現在擁有這家醫療設備提供商1,560,137股票，價值21,545,000美元，上個季度又購買了486,631股票。馬歇爾·華斯有限責任公司在第四季度增持了4.2%的BioLife Solutions股份。馬歇爾·華斯有限責任公司在上個季度購買了54,502股後，現在擁有這家醫療設備提供商1,346,746股股票，價值50,193,000美元。最後，道富銀行在第二季度增持了26.1%的BioLife Solutions股份。道富集團目前持有這家醫療設備提供商1,270,364股股票，價值17,544,000美元，上一季度又購買了263,021股。86.69%的股票由機構投資者和對衝基金持有。

BioLife Solutions Company Profile

BioLife Solutions公司簡介

(Get Rating)

(獲取評級)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions，Inc.為美國、加拿大、歐洲、中東、非洲和國際上的細胞和基因治療行業開發、製造和提供生物生產工具和服務。該公司的產品用於基礎和應用研究，以及基於生物的療法的商業製造。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • General Mills: Superior Returns With Less Volatility
  • 3 Defensive Stocks With 60-Year Dividend Hike Streaks
  • 3 Airline Stocks Stuck in a Holding Pattern
  • Roku Stock is Down but Not Out
  • If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
  • 免費獲取StockNews.com關於BioLife解決方案的研究報告(BLFS)
  • 通用磨坊：波動性更小、回報更高
  • 連續60年提高股息的3只防御性股票
  • 3家航空公司股票陷入持有格局
  • Roku股票下跌，但並未出局
  • 如果你渴望價值，那就嚐嚐露絲的好客之道吧

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有關BioLife解決方案的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioLife Solutions和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論